Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Tagging a Vibrio cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter enzyme: Clostridium thermocellum endoglucanase A.

Robert A, Silva A, Benitez JA, Rodriguez BL, Fando R, Campos J, Sengupta DK, Boesman-Finkelstein M, Finkelstein RA.

Vaccine. 1996 Nov;14(16):1517-22.

PMID:
9014293
2.

The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.

García L, Jidy MD, García H, Rodríguez BL, Fernández R, Año G, Cedré B, Valmaseda T, Suzarte E, Ramírez M, Pino Y, Campos J, Menéndez J, Valera R, González D, González I, Pérez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Pérez JL, Talavera A, Pérez A, Marrero K, Ledón T, Fando R.

Infect Immun. 2005 May;73(5):3018-24.

3.

CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.

Michalski J, Galen JE, Fasano A, Kaper JB.

Infect Immun. 1993 Oct;61(10):4462-8.

5.

Secretion and glycosylation of Clostridium thermocellum endoglucanase A encoded by the celA gene in Saccharomyces cerevisiae.

Benitez J, Silva A, Vazquez R, Noa MD, Hollenberg CP.

Yeast. 1989 Jul-Aug;5(4):299-306.

PMID:
2675490
6.

Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains.

Benítez JA, Silva AJ, Rodríguez BL, Fando R, Campos J, Robert A, García H, García L, Pérez JL, Oliva R, Torres CA, Ledón T.

Arch Med Res. 1996 Autumn;27(3):275-83.

PMID:
8854382
7.

Cell-associated hemagglutinin-deficient mutant of Vibrio cholerae.

Finn TM, Reiser J, Germanier R, Cryz SJ Jr.

Infect Immun. 1987 Apr;55(4):942-6.

8.
9.
10.

Construction and characterisation of O139 cholera vaccine candidates.

Ledón T, Valle E, Valmaseda T, Cedré B, Campos J, Rodríguez BL, Marrero K, García H, García L, Fando R.

Vaccine. 2003 Mar 7;21(11-12):1282-91.

PMID:
12559810
11.

Expression of foreign proteins in a Vibrio cholerae vaccine strain using the stationary phase hemagglutinin/protease promoter.

Hazra A, Silva AJ, Benitez JA.

Biotechnol Lett. 2007 Jul;29(7):1093-7. Epub 2007 Apr 13.

PMID:
17431549
12.

Pathogenic and vaccine significance of toxin-coregulated pili of Vibrio cholerae E1 Tor.

Attridge SR, Voss E, Manning PA.

J Biotechnol. 1999 Aug 20;73(2-3):109-17. Review.

PMID:
10486921
13.

New E. coli cloning vector using a cellulase gene (celA) as a screening marker.

Jang SJ, Park WJ, Chung SK, Jeong CY, Chung DK.

Biotechniques. 2001 Nov;31(5):1064, 1066, 1068.

PMID:
11730014
14.

A review of the current status of enteric vaccines.

Levine MM, Noriega F.

P N G Med J. 1995 Dec;38(4):325-31. Review.

PMID:
9522876
15.

Construction and characterization of a nonproliferative El Tor cholera vaccine candidate derived from strain 638.

Valle E, Ledón T, Cedré B, Campos J, Valmaseda T, Rodríguez B, García L, Marrero K, Benítez J, Rodríguez S, Fando R.

Infect Immun. 2000 Nov;68(11):6411-8.

16.

Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate.

Benítez JA, García L, Silva A, García H, Fando R, Cedré B, Pérez A, Campos J, Rodríguez BL, Pérez JL, Valmaseda T, Pérez O, Pérez A, Ramírez M, Ledón T, Jidy MD, Lastre M, Bravo L, Sierra G.

Infect Immun. 1999 Feb;67(2):539-45.

17.
18.

CTXphi immunity: application in the development of cholera vaccines.

Kimsey HH, Waldor MK.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7035-9.

20.

The Vibrio cholerae mannose-sensitive hemagglutinin is the receptor for a filamentous bacteriophage from V. cholerae O139.

Jouravleva EA, McDonald GA, Marsh JW, Taylor RK, Boesman-Finkelstein M, Finkelstein RA.

Infect Immun. 1998 Jun;66(6):2535-9.

Supplemental Content

Support Center